IMPORTANCE The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol management guidelines identified 2 distinct groups of patients with atherosclerotic cardiovascular disease (ASCVD) prompting different treatment recommendations.

OBJECTIVE To investigate whether the addition of high-sensitivity troponin (hsTn) testing to guideline-derived ASCVD risk can improve risk classification and downstream treatment recommendations.

DESIGN, SETTING, AND PARTICIPANTS A prospective cohort biomarker substudy was performed that included 8635 patients enrolled in the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Patients were assigned to risk groups of either very high-risk ASCVD or lower-risk ASCVD based on their cardiovascular history and comorbidities, in line with the 2018 AHA/ACC cholesterol management guidelines criteria. Patients were also classified on the basis of hsTnI level (ARCHITECT assay; Abbott) using cut points of 2 ng/L (limit of detection) and 6 ng/L (risk threshold), followed by joint classification on the basis of clinical features and hsTnI level. The setting was a nested prospective cohort study in a completed multinational trial. Participants were all patients who had a myocardial infarction 1 to 3 years before enrollment, were at least 50 years of age, and had at least 1 high-risk feature. The study dates were October 2010 to December 2014. The dates of analysis were June 2019 to January 2020.

MAIN OUTCOMES AND MEASURES The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke.

RESULTS Among 8635 patients enrolled in the PEGASUS-TIMI 54 trial, the median age was 65 years (interquartile range, 58-71 years), and 6614 (76.6%) were men; 8340 (96.6%) were White individuals and 176 (2.0%) were Black individuals. Patients meeting clinical criteria for the very high-risk ASCVD group had a primary end point 3-year event rate of 8.8% compared with 5.0% in the lower-risk ASCVD group (hazard ratio, 2.01; 95% CI, 1.58-2.57; \( P < .001 \)). When patients in the very high-risk ASCVD group were further risk stratified by hsTnI level, 614 of 6789 patients (9.0%) with an undetectable hsTnI level had a 3-year event rate of 2.7% (<1% per year), which was less than the overall rate in the lower-risk ASCVD group. Analogously, in the lower-risk ASCVD group, 417 of 1846 patients (22.6%) with an hsTnI level exceeding 6 ng/L had an event rate of 9.1%, comparable to the overall rate in the very high-risk ASCVD group. The addition of hsTnI to guideline-derived ASCVD risk led to a net reclassification index at event rate of 0.15 (95% CI, 0.10-0.21). Overall, use of hsTnI reclassified 1031 of 8635 patients (11.9%) (1 in 11 with very high-risk ASCVD and 1 in 4 with lower-risk ASCVD).

CONCLUSIONS AND RELEVANCE The findings of this cohort substudy suggest that a strategy incorporating hsTn into a guideline-derived ASCVD risk algorithm provides enhanced risk stratification and reclassifies 11.9% of patients into a more appropriate risk group. This application of hsTn testing might be used to optimize the care of patients with ASCVD.
High-sensitivity troponin (hsTn) has demonstrated a strong association with recurrent events in patients with stable atherosclerotic cardiovascular disease (ASCVD), yet it is still not routinely being used in clinical practice in this population. A recent study in patients with hypertension suggests that hsTnI could be used to refine risk categorization and better identify who should receive antihypertensive therapies. Decisions about cholesterol management may be another opportunity to incorporate hsTn testing into clinical risk algorithms that inform downstream treatment recommendations.

The 2018 American Heart Association/American College of Cardiology (AHA/ACC) cholesterol management guidelines identified 2 distinct groups of patients with ASCVD. The first is a very high-risk group classified by the presence of 2 or more major cardiovascular (CV) events or 1 major event with multiple high-risk conditions. The second group includes the remainder of patients with ASCVD, designated in the cholesterol management guidelines as not at very high risk, who have established atherosclerotic disease but do not meet the 2018 AHA/ACC guidelines criteria for very high risk and are hereafter referred to as lower risk. Based on this clinical risk stratification, the recommendations for the 2 groups differ in 3 important ways. First, patients in the very high-risk ASCVD group are to be treated with high-intensity statin independent of age, as opposed to the lower-risk ASCVD group, in which statin therapy is a class I recommendation only for patients 75 years or younger. Second, ezetimibe is a class IIa recommendation in very-high-risk ASCVD and only a class IIb recommendation in lower-risk ASCVD. Third, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are recommended as class IIIa for patients in the very high-risk ASCVD group with low-density lipoprotein cholesterol (LDL-C) levels of 70 mg/dL or higher but are not recommended for the lower-risk ASCVD group (to convert cholesterol level to millimoles per liter, multiply by 0.0259).

The clinical distinctions made in the AHA/ACC cholesterol management guidelines are a step toward a more personalized approach to treating most patients with ASCVD. However, inherent to the success of such a strategy is the robustness of risk stratification. The present study investigated whether the addition of hsTn to guideline-derived ASCVD risk can improve risk classification and guide downstream treatment recommendations.

### Methods

#### Study Population

A prospective cohort biomarker substudy was performed that included 8635 patients enrolled in the Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. PEGASUS-TIMI 54 was a multinational randomized trial comparing ticagrelor with placebo in patients with prior myocardial infarction (MI). The study design and results of the trial have previously been published. The present exploratory analysis uses data from the prospective cohort biomarker substudy to evaluate hsTnI level for risk evaluation within the framework of the 2018 AHA/ACC cholesterol management guidelines. The analysis includes all consenting patients with available blood samples in the prospective cohort biomarker substudy. Data from this analysis will not be made publicly available. Informed consent was obtained from all participating individuals. The trial protocol was reviewed and approved by the institutional review board or ethics committee at each participating center.

For this analysis, patients were assigned to guideline-derived risk groups of either very high-risk ASCVD or a lower-risk ASCVD based on their CV history and comorbidities, in line with the 2018 AHA/ACC cholesterol management guidelines criteria. Patients were also classified on the basis of hsTnI level using cut points of 2 ng/L (limit of detection) and 6 ng/L (risk threshold) and joint classification on the basis of clinical features and hsTnI level. The setting was a nested prospective cohort study in a completed multinational trial. Participants were all patients who had an MI 1 to 3 years before enrollment, were at least 50 years of age, and had at least 1 high-risk feature. The study dates were October 2010 to December 2014. The dates of analysis were June 2019 to January 2020.

To qualify for the very high-risk ASCVD group, patients had to have either (1) at least 2 prior major CV events (acute coronary syndrome within the past 12 months, history of MI before the preceding 12 months, history of ischemic stroke, or peripheral vascular disease, as defined by revascularization, amputation, or claudication, with documented ankle-brachial index <0.90) or (2) a single prior major event plus multiple high-risk conditions (age ≥65 years, prior coronary revascularization, diabetes, hypertension, current smoking, apolipoprotein B [apoB] level ≥90 mg/dL [to convert apoB level to grams per liter, multiply by 0.01] despite statin therapy, prior congestive heart failure, or chronic kidney disease [estimated glomerular filtration rate ≤60 mL/min/1.73 m²]). The apoB level was used as a surrogate for LDL-C level because it was the atherogenic lipoprotein measurement available in the...
High-Sensitivity Troponin Testing in the ASCVD Framework of the Current Cholesterol Guidelines

End Points
The prespecified primary end point of the trial was a composite of CV death, MI, or stroke. Secondary end points included the individual components of the primary outcome, as well as death from coronary heart disease and death from any cause. Patients were followed up for a median of 33 months (interquartile range, 27-38 months). All CV end points were adjudicated by a central clinical events committee that was blinded to treatment assignment and baseline hsTnI level.

Statistical Analysis
Baseline characteristics stratified by guideline-derived ASCVD risk group and by hsTnI level are listed in the Table. Continuous variables within each group are presented as median and interquartile range and compared using the Wilcoxon rank sum test. Categorical variables between ASCVD risk groups were compared using the χ² test. Continuous variables were analyzed by analysis of variance with P for linear trend, and categorical variables were analyzed using the Cochran-Armitage test for trend. Three-year event rates were estimated using the Kaplan-Meier method. Hazard ratios (HRs) and 95% CIs were generated using a Cox proportional hazards regression model. Adjusted regression models for the association of hsTnI level with clinical outcomes included age, sex, history of peripheral artery disease, diabetes, hypertension, smoking, apoB level, prior congestive heart failure, estimated glomerular filtration rate, stroke, and coronary artery bypass graft. The net reclassification index at event rate and integrated discrimination improvement index were calculated in models with guideline-derived ASCVD only and with

Table. Baseline Characteristics by Guideline-Derived ASCVD Risk Group and hsTnI Level

<table>
<thead>
<tr>
<th>Variable</th>
<th>ASCVD risk group, No./total No. (%)</th>
<th>hsTnI level, No./total No. (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lower-risk ASCVD (n = 1846)</td>
<td>Very high-risk ASCVD (n = 6789)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;2 ng/L (n = 920)</td>
<td>2-6 ng/L (n = 5028)</td>
<td>&gt;6 ng/L (n = 2687)</td>
</tr>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Age, median (IQR), y                                          | 60 (55-64)                          | 67 (60-72)                     | 61 (55-66)  
|                                                               | 65 (58-70)                          | 67 (60-73)                     | .001     |
| Age ≥65 y                                                     | 397 (21.5)                          | 4186 (61.7)                    | 337 (36.6)  
|                                                               | 2658 (52.9)                         | 1588 (59.1)                    | .001     |
| Female                                                        | 232 (12.6)                          | 1789 (26.4)                    | 330 (35.9)  
|                                                               | 1137 (22.6)                         | 554 (20.6)                     | .001     |
| Medical history                                               |                                     |                                |         |
| Prior MI                                                      | 1846 (100)                          | 6789 (100)                     | 920 (100)   
|                                                               | 5028 (100)                          | 2687 (100)                     | NA       |
| History of peripheral artery disease                         | 24 (1.3)                            | 540 (8.0)                      | 29 (3.2)    
|                                                               | 296 (5.9)                           | 239 (8.9)                      | .001     |
| Prior coronary revascularization                              | 1753 (95.0)                         | 6346/6788 (93.5)               | 877 (95.3)  
|                                                               | 4720/5027 (93.9)                    | 2502 (93.1)                    | .02      |
| Diabetes                                                      | 87 (4.7)                            | 2489 (36.7)                    | 269 (29.2)  
|                                                               | 1391 (27.7)                         | 916 (34.1)                     | .001     |
| Hypertension                                                  | 752 (40.7)                          | 6012 (88.6)                    | 644 (70.0)  
|                                                               | 3905 (77.7)                         | 2215 (82.4)                    | .001     |
| Current smoker                                                | 99/1845 (5.4)                       | 1506/6788 (22.2)               | 220/919 (23.9)  
|                                                               | 945 (18.8)                          | 440/2686 (16.4)                | <.001    |
| apoB level ≥90 mg/dL despite statin therapy                   | 115/1803 (6.4)                      | 1893/6668 (28.4)               | 212/902 (23.5)  
|                                                               | 1181/4929 (24.0)                    | 615/2640 (23.3)                | .71      |
| Prior congestive heart failure                                | 32 (1.7)                            | 1300 (19.1)                    | 63 (6.8)    
|                                                               | 610 (12.1)                          | 659 (24.5)                     | <.001    |
| Laboratory values                                            |                                     |                                |         |
| Estimated glomerular filtration rate <60 mL/min/1.73 m²       | 23/1828 (1.3)                       | 1973/6736 (29.3)               | 105/909 (11.6)  
|                                                               | 1007/4985 (20.2)                    | 884/2670 (31.1)                | <.001    |
| hsTnI level, median (IQR), ng/L                               | 4 (2-6)                             | 4 (3-8)                        | <2b        
|                                                               | 4 (3-5)                             | 10 (8-17)                      | NA       |

Abbreviations: apoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; hsTnI, high-sensitivity troponin I; IQR, interquartile range; MI, myocardial infarction; NA, not applicable. 

a The hsTnI levels for 8340 White individuals (1795 lower-risk ASCVD and 6545 very high-risk ASCVD) were less than 2 ng/L in 892 individuals (97.0%), 2 to 6 ng/L in 91 individuals (1.8%), and greater than 6 ng/L in 2571 individuals (95.7%) (P = .008). The hsTnI levels for 176 Black individuals (26 lower-risk ASCVD and 150 very high-risk ASCVD) were less than 2 ng/L in 11 individuals (95.7%) (<.001), 2 to 6 ng/L in 91 individuals (1.8%), and greater than 6 ng/L in 74 individuals (2.8%) (P = .001). 

b Presented without IQR because values less than 2 ng/L are below the level of detection for the assay.

© 2020 American Medical Association. All rights reserved.

PEGASUS-TIMI 54 trial.10 The threshold of 90 mg/dL for apoB level approximates 100 mg/dL for LDL-C level.11,12 The remainder of patients qualified for the lower-risk ASCVD group because of their established atherosclerosis as evident by a prior MI.

Troponin Assay
Patients had baseline blood samples collected at the time of study enrollment. Cardiac troponin I level was measured centrally (at the TIMI Clinical Trials Laboratory, Boston, Massachusetts) using a now clinically available, high-sensitivity assay (ARCHITECT assay; Abbott), which has a limit of detection of 2 ng/L, and previous studies have demonstrated thresholds of risk in the range of 5 to 7 ng/L. Therefore, we categorized patients into the following 3 a priori groups for risk stratification based on hsTnI results: undetectable (<2 ng/L), low (2-6 ng/L), and high (>6 ng/L). These values chosen for risk stratification in this cohort of stable patients are well below the 99th percentile upper reference limit of 26 ng/L (34 ng/L in men and 16 ng/L in women) recommended for the diagnosis of acute MI.20 The coefficient of variation at the 99th percentile of the assay is 5.6%.20

Published: November 2020 Volume 5, Number 11

jamacardiology.com

© 2020 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ on 09/16/2023
hsTnI level. To evaluate the incremental value of hsTnI level beyond guideline-derived ASCVD risk, the likelihood ratio test was used.23 All reported P values are 2 sided at a statistical significance level of .05. All analyses were performed with SAS software (version 9.4; SAS Institute Inc).

Results

Patients

Of the 8635 patients in this biomarker substudy (eTable 1 in the Supplement), the median age was 65 years (interquartile range, 58-71 years), and 6614 (76.6%) were men; 8340 (96.6%) were White individuals and 176 (2.0%) were Black individuals. Based on clinical criteria, 6789 patients (78.6%) were in the very high-risk ASCVD group, with most (6342 of 6789 [93.4%]) qualifying based on 1 major event and multiple high-risk conditions and fewer (447 of 6789 [6.6%]) qualifying with at least 2 major adverse events. The remaining 1846 patients (21.4%) were in the lower-risk ASCVD group, in which all patients had 1 major event, 1511 had 1 additional high-risk feature, and 335 had none. Overall, 8199 of 8635 patients (95.0%) were receiving statin therapy. Baseline characteristics for the 2 ASCVD groups are listed in the Table.

The median hsTnI level was 4 ng/L (interquartile range, 3-7 ng/L). Overall, 7715 of 8635 patients (89.3%) had a detectable hsTnI level (>2 ng/L). Of those with a detectable hsTnI level, 5028 of 7715 (65.2%) had levels between 2 and 6 ng/L, and 2687 of 7715 (34.8%) had levels exceeding 6 ng/L. Patients with baseline hsTnI level exceeding 6 ng/L were more likely to be older, to be male, and to have comorbidities, including prior coronary revascularization, diabetes, hypertension, prior congestive heart failure, and chronic kidney disease (Table).

Very High-Risk ASCVD vs Lower-Risk ASCVD

Of the 8635 patients in this analysis, 610 (7.1%) experienced a primary end point event (CV death, MI, or stroke). Patients meeting clinical criteria for the very high-risk ASCVD group had a statistically significantly higher rate of CV death, MI, or stroke, with a 3-year Kaplan-Meier event rate of 8.8% compared with 5.0% in the lower-risk ASCVD group (hazard ratio [HR], 2.01; 95% CI, 1.58-2.57; P < .001). Stratifying those with hsTnI levels of 6 ng/L or less into undetectable (<2 ng/L) and low (2-6 ng/L) levels identified patients with 3-year event rates of 2.8% and 6.0%, respectively, with a 3-year event rate of 13.5% in patients with hsTnI levels exceeding 6 ng/L. In the adjusted regression model, compared with patients with undetectable hsTnI levels, those with hsTnI levels of 2 to 6 ng/L were at a more than 2-fold higher risk (adjusted HR, 2.38; 95% CI, 1.47-3.85; P < .001) of adverse events, and those with hsTnI levels exceeding 6 ng/L were at an almost 5-fold higher risk (adjusted HR, 4.83; 95% CI, 2.98-7.84; P < .001).

Figure 1. Kaplan-Meier Rates for the Primary End Point (a Composite of Cardiovascular [CV] Death, Myocardial Infarction [MI], or Stroke) by Guideline-Derived Atherosclerotic Cardiovascular Disease (ASCVD) Risk Group and High-Sensitivity Troponin I (hsTnI) Level

A. Patients meeting clinical criteria for the very high-risk ASCVD group had a statistically significantly higher rate of CV death, MI, or stroke, with a 3-year Kaplan-Meier event rate of 8.8% compared with 5.0% in the lower-risk ASCVD group (hazard ratio [HR], 2.01; 95% CI, 1.58-2.57; P < .001). B. Stratifying those with hsTnI levels of 6 ng/L or less into undetectable (<2 ng/L) and low (2-6 ng/L) levels identified patients with 3-year event rates of 2.8% and 6.0%, respectively, with a 3-year event rate of 13.5% in patients with hsTnI levels exceeding 6 ng/L. In the adjusted regression model, compared with patients with undetectable hsTnI levels, those with hsTnI levels of 2 to 6 ng/L were at a more than 2-fold higher risk (adjusted HR, 2.38; 95% CI, 1.47-3.85; P < .001) of adverse events, and those with hsTnI levels exceeding 6 ng/L were at an almost 5-fold higher risk (adjusted HR, 4.83; 95% CI, 2.98-7.84; P < .001).
High-Sensitivity Troponin Testing in the ASCVD Framework of the Current Cholesterol Guidelines

Original Investigation Research

Figure 2. Adjusted Hazard Ratio (HR) for the Primary End Point, Myocardial Infarction (MI), Stroke, and All-Cause Mortality Stratified by High-Sensitivity Troponin I (hsTnI) Level

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Adjusted HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary end point</td>
<td>2.03 (1.71-2.41)</td>
</tr>
<tr>
<td>MI</td>
<td>1.90 (1.55-2.33)</td>
</tr>
<tr>
<td>Stroke</td>
<td>2.22 (1.47-3.35)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>1.81 (1.42-2.32)</td>
</tr>
</tbody>
</table>

Patients with undetectable hsTnI levels (<2 ng/L) were at statistically significantly lower risk (adjusted HR, 0.42; 95% CI, 0.26-0.68; P < .001) of the primary end point, and patients with hsTnI levels exceeding 6 ng/L were at 2-fold higher risk (adjusted HR, 2.03; 95% CI, 1.71-2.41; P < .001). All-cause mortality is shown rather than CV death because there were no CV deaths in patients with hsTnI levels less than 2 ng/L, precluding calculation of an HR.

Integrating hsTnI Level Into the Cholesterol Guidelines

Risk Schema

When patients in the guideline-derived very high-risk ASCVD group (overall 3-year event rate of 8.8%) were further risk stratified by hsTnI level, 9.0% (614 of 6789), 57.5% (3905 of 6789), and 33.4% (2270 of 6789) had an hsTnI level less than 2 ng/L, 2 to 6 ng/L, and greater than 6 ng/L, respectively. The 3-year event rates for CV death, MI, or stroke were 2.7% in patients with an hsTnI level less than 2 ng/L, 6.5% in patients with an hsTnI level of 2 to 6 ng/L, and 14.3% in patients with an hsTnI level exceeding 6 ng/L (P for trend <.001) (Figure 3). Of 6789 patients, 614 (9.0%) had discordant ASCVD risk and hsTnI level (very high clinical risk and undetectable hsTnI level), a 3-year event rate of 2.7% (<1% per year), and risk that was less than that of the overall rate in the guideline-derived lower-risk ASCVD group (Figure 4 and eTable 3 in the Supplement).

Likewise, in the lower-risk ASCVD group (overall 3-year event rate of 5.0%), hsTnI levels also provided a further gradient of risk. In this group, 16.6% (306 of 1846), 60.8% (1123 of 1846), and 22.6% (417 of 1846) of patients had an hsTnI level less than 2 ng/L, 2 to 6 ng/L, and greater than 6 ng/L, respectively. The 3-year event rates for CV death, MI, or stroke were 3.1% in patients with an hsTnI level less than 2 ng/L, 4.0% in patients with an hsTnI level of 2 to 6 ng/L, and 9.1% in patients with an hsTnI level exceeding 6 ng/L (P for trend <.001) (Figure 3). Of 1846 patients, 417 (22.6%) had discordant ASCVD risk and hsTnI level (lower ASCVD risk and hsTnI level >6 ng/L) and had a 3-year event rate of 9.1%, comparable to the overall rate in the guideline-derived very high-risk ASCVD group (8.8%) (Figure 4).

The addition of hsTnI level to guideline-derived ASCVD risk led to a statistically significant improvement in the model for the primary end point (likelihood ratio test P < .001). Additional metrics of reclassification were also statistically significant and are listed in eTable 4 in the Supplement. The addition of hsTnI to guideline-derived ASCVD risk led to an improved net reclassification index at event rate of 0.15 (95%
CI, 0.10-0.21) and integrated discrimination improvement index of 0.03 (95% CI, 0.03-0.04). Overall, use of hsTnI reclassified 1031 of 8635 patients (11.9%) (1 in 11 with very high-risk ASCVD and 1 in 4 with lower-risk ASCVD), whose guideline-derived clinical risk assignment would be altered (eTable 5 in the Supplement).

Discussion
This analysis highlights 3 key findings related to the current AHA/ACC cholesterol management guidelines\(^9\) risk stratification scheme and the potential for integration of hsTnI testing into risk stratification. First, the current guidelines’ approach to risk stratification in patients with ASCVD identifies 2 distinct groups at different risk for future major CV events. Second, hsTnI level alone stratifies risk, as well as the guideline-derived ASCVD risk groups. Third, hsTnI level provides CV risk stratification that is additive to the guideline-defined ASCVD groups and reclassifies risk appropriately.

Not all patients with ASCVD are at equivalent risk and, depending on their severity of disease and comorbidities, may have differing recommendations for certain therapies. For example, the very high-risk ASCVD group has a class IIa recommendation for both ezetimibe and PCSK9 inhibitors, whereas in lower-risk ASCVD patients there is only a class IIb recommendation for ezetimibe and no recommendation for a PCSK9 inhibitor.\(^3\) However, if one is preferentially recommending proven CV therapies to certain groups based on their perceived risk, it is critical to first demonstrate that the defined group is truly at higher risk, and second that each individual’s risk is classified as accurately as possible to ensure that the right patients are receiving the desired therapies.

The first of these 2 key goals was achieved by the recent AHA/ACC cholesterol management guidelines,\(^9\) consistent with other recent work.\(^2-4\) The clinical framework did in fact identify patients at higher clinical risk, with a 2-fold higher event rate in our prospective cohort biomarker substudy population. This relative risk may be an underestimate in this prior MI population given the absence of patients without a history of any major events. Therefore, the difference in risk between our 2 study groups may actually be greater among all ASCVD populations. However, our observed annualized CV event rate of approximately 3% (8.8% divided by 3) per year is likely a reasonable estimate for very high-risk ASCVD.

hsTnI Level and Lipid Therapy
Measurement of hsTnI might easily and affordably identify patients who are at low, intermediate, and high CV risk using hsTnI cut points of 2 and 6 ng/L to stratify patients with stable ischemic heart disease into low-risk (<1% per year), intermediate-risk (1%-3% per year), and high-risk (3%-6% per year) cohorts. Compared with patients at intermediate (average) risk, hsTnI level identifies not only patients who are at 2-fold higher risk when exceeding 6 ng/L but also those with a statistically significantly lower risk when less than 2 ng/L. Furthermore, among the 10.7% (920 of 8635) of patients with an undetectable hsTnI level, there were no CV deaths during the approximate 3-year follow-up in this study.

A key finding of this study is that risk stratification using hsTnI appears to be complementary to the 13 clinical risk factors in the guideline-based ASCVD framework. Indeed, the addition of hsTnI level gives a more granular estimate of CV risk. For example, the very high-risk patients with ASCVD and an undetectable hsTnI level have an annu-

---

**Figure 4. Reclassification of Cardiovascular Risk With the Addition of High-Sensitivity Troponin I (hsTnI) Level**

<table>
<thead>
<tr>
<th>No. at risk</th>
<th>Lower-risk ASCVD (hsTnI level ≤6 ng/L)</th>
<th>Lower-risk ASCVD (hsTnI level &gt;6 ng/L)</th>
<th>Very high-risk ASCVD (hsTnI level &lt;2 ng/L)</th>
<th>Very high-risk ASCVD (hsTnI level ≥2 ng/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1429</td>
<td>1418</td>
<td>1410</td>
<td>1361</td>
</tr>
<tr>
<td>Time, d</td>
<td>1361</td>
<td>1361</td>
<td>1361</td>
<td>1361</td>
</tr>
<tr>
<td>CV death, MI, or stroke, %</td>
<td>1173</td>
<td>1173</td>
<td>1173</td>
<td>1173</td>
</tr>
<tr>
<td></td>
<td>384</td>
<td>384</td>
<td>384</td>
<td>384</td>
</tr>
<tr>
<td></td>
<td>334</td>
<td>334</td>
<td>334</td>
<td>334</td>
</tr>
<tr>
<td></td>
<td>249</td>
<td>249</td>
<td>249</td>
<td>249</td>
</tr>
<tr>
<td></td>
<td>129</td>
<td>129</td>
<td>129</td>
<td>129</td>
</tr>
<tr>
<td></td>
<td>881</td>
<td>881</td>
<td>881</td>
<td>881</td>
</tr>
<tr>
<td></td>
<td>447</td>
<td>447</td>
<td>447</td>
<td>447</td>
</tr>
</tbody>
</table>

ASCVD indicates atherosclerotic cardiovascular disease; CV, cardiovascular; and MI, myocardial infarction.
alized CV event rate of less than 1% (2.7% divided by 3) per year, reclassifying them as very low risk. In contrast, lower-risk patients with ASCVD and hsTnI level exceeding 6 ng/L carry an annualized CV event risk similar to that of the very high-risk ASCVD group. This approach identifies 20% to 25% of lower-risk patients with ASCVD who might be considered for ezetimibe or PCSK9 inhibition in the same way as very high-risk patients with ASCVD. In addition, clinically very high-risk patients with ASCVD and undetectable hsTnI levels may warrant management with similar strategies as those recommended for lower-risk (ie, not very high-risk) patients with ASCVD. These analyses suggest that incorporating an inexpensive and widely available biomarker into ASCVD risk assessment could both improve risk stratification and ensure that patients are offered risk-appropriate medical therapies.

Our findings relative to the current AHA/ACC cholesterol management guidelines are consistent with the application of hsTnI to the 2017 AHA/ACC high blood pressure guidelines. Both studies found that the incorporation of hsTnI improves risk stratification and identifies patients who may warrant more aggressive preventive therapies. In conjunction with the accumulated strong and consistent evidence for the predictive value of hsTnI level in stable patients with ASCVD, these findings support consideration of its implementation for risk-based therapeutic selection in clinical practice.

Limitations
The results of this study must be interpreted in the context of the study design. All patients in the analysis had a history of MI; therefore, the findings may not be generalizable to all ASCVD populations. The analyses were based on a prospective cohort biomarker substudy of patients with different hsTnI levels, as opposed to continuous data, which leads to a loss in power. However, use of cut points is often helpful for clinical decision-making and structured risk stratification, as in the cholesterol guidelines risk schema. In addition, these results are based on a particular hsTnI assay, and we cannot extrapolate to similar cut points for other troponin assays. This study was an exploratory analysis of the 2018 AHA/ACC cholesterol management guidelines risk groups, published after the prospective cohort biomarker substudy was designed. Some components of the guidelines’ risk stratification approach were not available, such as LDL-C level, and apoB level was used as a surrogate.

Conclusions
The findings of this cohort substudy suggest that a strategy incorporating hsTnI testing into a guideline-derived ASCVD risk algorithm provides enhanced risk stratification and reclassifies patients into more appropriate risk groups. This application of hsTnI might be used to optimize the care of patients with ASCVD.
Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, and Zara Biosciences. Dr Braunwald reported receiving grants from AstraZeneca, Daiichi Sankyo, Merck, and Novartis and receiving personal fees from Amgen, Cardurion, Myokardia, Novo Nordisk, and Verve. Dr Sabatine reported receiving research grant support through Brigham and Women's Hospital from Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Takeda, and The Medicines Company and receiving consulting fees from Amgen, Anthos Therapeutics, AstraZeneca, Bristol-Myers Squibb, CVS Caremark, DaiCoS, Dymaxim, Esperion, IFM Therapeutics, Intarcia, Ionis, Janssen, MedImmune, Merck, Novartis, and The Medicines Company. Dr Sabatine reported being a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women's Hospital from Abbott Laboratories, Arale, Roche, and Zara Biosciences. Dr Morrow reported receiving grants to Brigham and Women's Hospital from Abbott Laboratories, AstraZeneca, BRAHMS, Daiichi Sankyo, Eisai, GlaxoSmithKline, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, and Zara Biosciences and receiving consulting fees from Arale, AstraZeneca, Bayer, InCarda, Novartis, and Roche. No other disclosures were reported.

Funding/Support: The long-term use of Ticagrelor in Patients With Prior Myocardial Infarction (PEGASUS-TIMI 54) trial was sponsored by AstraZeneca. Reagent support was provided by Abbott Laboratories.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES


© 2020 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ on 09/16/2023